EyePoint Pharmaceuticals Investor Presentation May 2024

EyePoint Pharmaceuticals presents its pipeline of intravitreal drug delivery candidates, including DURAVYU (vorolanib) for wet AMD and NPDR, and EYP-2301 (razuprotafib) for retinal diseases, leveraging its proprietary Durasert platform. The company reports $299M in cash with runway through Phase 3 wet AMD trial topline data in 2026.